TD Cowen analyst Tyler Van Buren maintained a Hold rating on Crispr Therapeutics AG yesterday and set a price target of $40.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tyler Van Buren has given his Hold rating due to a combination of factors impacting Crispr Therapeutics AG. The company’s recent financial performance, particularly the costs associated with Casgevy, has raised concerns about its ability to achieve profitability in the near term. Despite encouraging sales guidance for Casgevy, the expenses continue to outpace revenue, indicating that profitability may still be distant.
Additionally, while Crispr Therapeutics has reported promising Phase I data for its CTX310 program targeting dyslipidemias, the overall progress of its pipeline remains a mixed bag. The company is advancing some programs, like CTX112, but deprioritizing others, such as CTX131. These developments suggest that while there is potential for future growth, there are also significant uncertainties that justify a cautious approach, leading to the Hold rating.
In another report released yesterday, Clear Street also maintained a Hold rating on the stock with a $50.00 price target.